# Biovie Inc.: overview BIVI · Nasdaq · CIK 1580149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/bivi.md) · [Financials](/companies/bivi/financials.md) · [Filings](/companies/bivi/filings.md) · [Insiders](/companies/bivi/insiders.md) Latest reported revenue: [$0](/filings/0001520138-17-000020.md) for Q1 FY2017, three months to 2016-09-30, from the 10-Q/A filed Jan 19, 2017 (XBRL us-gaap:SalesRevenueNet, accession 0001520138-17-000020). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(7.00)](/filings/0001520138-25-000343.md) | [(4.55)](/filings/0001520138-26-000052.md) | [(1.51)](/filings/0001520138-26-000154.md) | not reported | [(0.98)](/filings/0001520138-25-000343.md) | [(0.77)](/filings/0001520138-26-000052.md) | [(0.70)](/filings/0001520138-26-000154.md) | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.06)](/filings/0001520138-23-000325.md) | [(15.47)](/filings/0001520138-24-000324.md) | [(73.05)](/filings/0001520138-25-000268.md) | [(12.12)](/filings/0001520138-26-000332.md) | [(3.05)](/filings/0001520138-26-000332.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bivi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.2m | 605,471 | | Added +530,250 | | [Diametric Capital, LP](/funds/1719087.md) | 2026-06-30 | $497.9k | 256,636 | | Reduced −113,364 | | [Diametric Capital, LP](/funds/1719087.md) | 2026-06-30 | $337.5k | 750,000 | | Unchanged | | [Warberg Asset Management LLC](/funds/1597506.md) | 2026-06-30 | $276.0k | 613,426 | | Added +156,797 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $248.2k | 127,918 | | Added +60,000 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $225.0k | 500,000 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $186.1k | 95,952 | | Added +50,660 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $137.6k | 70,906 | | Reduced −13,161 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $137.3k | 70,752 | | Reduced −13,451 | | [PRELUDE CAPITAL MANAGEMENT, LLC](/funds/1387508.md) | 2026-06-30 | $84.0k | 186,621 | | Unchanged | ## Recent filings [All 502 filings](/companies/bivi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 17:13 ET | [DEF 14A](/filings/0001520138-26-000395.md) | Proxy statement, period 2026-09-28 | 0001520138-26-000395 | | 2026-09-14 | 18:16 ET | [8-K](/filings/0001520138-26-000391.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001520138-26-000391 | | 2026-08-14 | 17:23 ET | [S-1/A](/filings/0001520138-26-000350.md) | Registration statement, amended | 0001520138-26-000350 | | 2026-08-13 | 19:36 ET | [10-K](/filings/0001520138-26-000332.md) | Annual report, period 2026-06-30 | 0001520138-26-000332 | | 2026-08-06 | 07:41 ET | [S-1/A](/filings/0001520138-26-000313.md) | Registration statement, amended | 0001520138-26-000313 | | 2026-08-06 | 07:35 ET | [8-K](/filings/0001520138-26-000312.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001520138-26-000312 | | 2026-07-31 | 17:29 ET | [S-1/A](/filings/0001520138-26-000299.md) | Registration statement, amended | 0001520138-26-000299 | | 2026-07-17 | 17:21 ET | [S-1](/filings/0001520138-26-000276.md) | Registration statement | 0001520138-26-000276 | | 2026-05-11 | 16:56 ET | [10-Q](/filings/0001520138-26-000154.md) | Quarterly report, period 2026-03-31 | 0001520138-26-000154 | | 2026-03-25 | 17:00 ET | [SCHEDULE 13D](/filings/0001520138-26-000086.md) | Ownership report, active investor | 0001520138-26-000086 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001520138-26-000332.md), filed Aug 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1580149 - Tickers: BIVI, BIVIW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.